At the heart of Oncompass Medicine, there is a rigorously tested and reviewed molecular & clinical evidence.
Constantly evolving evidence-based medicine requires information generated at the highest evidence level. Oncompass refers primarily to the SANGER Institute’s COSMIC Catalogue of Somatic Mutations in Cancer database, and peer reviewed publications in PUBMED.
We also pay special attention to CANCER GENOME ATLAS projects, which are continuously expanding the genomic landscape of cancer types.
Certain biomarkers are included in drug registrations for certain tumor types (e.g. EGFR – gefitinib). Clinical trial publications might then indicate that a targeted drug can be effective in the presence of the predictive biomarkers in other tumor types (for example HER-2 – trastuzumab in colon cancer).
It is not uncommon that only case studies with dramatic results are published. To fill this potential knowledge gap (e.g. no preclinical data), Oncompass believes that molecular and biological evidence must be integrated in the decision-making algorithm.
Oncompass also firmly believes that its future focus must be on robust clinical results and biological associations rather than marginal effects, even if the latter are statistically proven.
We use a two-stage evidence ranking system. The first references the experiment type, similarly to classic evidence-based medicine. The second attempts to demonstrate the robustness of the data. As an example, KRAS mutations almost 100% exclude response to certain EGFR inhibitors, whereas data on the significance of PIK3CA mutations is not as robust.